Vicore Pharma Holding AB (VICO) AI Stock Analysis

• Market Cap: kr2.72B
• Dividend Yield: N/A
• Average Volume (3M): 614.68K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.70
• Revenue Growth: -94.25%
• EPS Growth: 9.47%
• Country: SE
• Employees: 33
• Sector: Healthcare
• Sector Strength: 49
• Industry: Biotechnology
• EPS (TTM): -0.48
• Shares Outstanding: 234,579,120
• 10 Day Avg. Volume: 1,248,997
• 30 Day Avg. Volume: 614,677
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: ―

Vicore Pharma Holding AB's stock is evaluated at a moderate level, reflecting its strong liquidity and financial resilience amidst continued net losses typical for biotech R&D phases. The technical analysis indicates potential short-term stability, while valuation remains tricky due to the negative P/E ratio. The absence of earnings call data and corporate events limits additional insights.

Vicore Pharma Holding AB Business Overview & Revenue Model

Company Description

Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; license agreement with Nanologica AB (publ); and a collaboration agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the Alex DTx platform. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.

How the Company Makes Money

Vicore Pharma Holding AB generates revenue primarily through the development and potential commercialization of its pharmaceutical candidates. The company's revenue model is largely dependent on the successful progression of its drug candidates through clinical trials, leading to potential licensing agreements, partnerships, or direct sales of approved therapies. Key revenue streams include milestone payments and royalties from strategic collaborations with larger pharmaceutical companies. Vicore Pharma may also seek funding through grants and public or private investments to support its research and development activities.

Vicore Pharma Holding AB Financial Statement Overview

Summary

Vicore Pharma Holding AB demonstrates financial resilience with strong cash positions and no debt, but faces profitability challenges common in early-stage biotech firms. The negative cash flow from operations and reliance on equity financing highlights the company's focus on R&D without immediate revenue returns.

Income Statement

Vicore Pharma Holding AB has shown significant challenges in profitability. The net profit margin remains negative due to high operating losses, despite a revenue increase in 2024. The gross profit margin is positive but primarily due to the revenue recognition without associated costs. The company exhibits a history of net losses, which is typical for early-stage biotech firms focusing on R&D.

Balance Sheet

The balance sheet is relatively strong with no debt and substantial cash reserves, indicating good liquidity. The equity ratio is high, which is positive for financial stability. However, the continuous accumulation of losses affects the return on equity, which remains negative. The company maintains a strong equity position, providing a buffer against operational risks.

Cash Flow

Cash flow from operations is consistently negative, reflecting the high costs associated with biotech R&D activities. Despite negative free cash flow, the company has managed to increase cash reserves significantly through financing activities, improving liquidity. The cash flow to net income ratios indicate reliance on financing rather than operational cash generation.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	109.35M	0.00	0.00	0.00	0.00
Gross Profit	109.35M	-3.42M	-3.61M	-3.60M	-3.54M
EBITDA	-166.64M	-317.47M	-286.20M	-293.13M	-143.77M
Net Income	-168.63M	-310.94M	-288.42M	-296.48M	-146.86M
Balance Sheet
Total Assets	1.20B	497.84M	338.01M	451.17M	406.51M
Cash, Cash Equivalents and Short-Term Investments	1.16B	482.66M	261.74M	371.20M	318.62M
Total Debt	0.00	0.00	65.00K	320.00K	140.00K
Total Liabilities	73.78M	42.45M	48.92M	67.85M	52.00M
Stockholders Equity	1.13B	455.39M	289.08M	383.32M	354.51M
Cash Flow
Free Cash Flow	-164.95M	-448.62M	-302.92M	-265.17M	-122.94M
Operating Cash Flow	-164.95M	-249.58M	-299.92M	-265.17M	-119.94M
Investing Cash Flow	149.04M	-144.46M	74.00M	-7.00M	4.00M
Financing Cash Flow	834.06M	470.86M	187.04M	318.18M	176.97M

Vicore Pharma Holding AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.58
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:VICO, the sentiment is Positive. The current price of 11.58 is above the 20-day moving average (MA) of 9.78, above the 50-day MA of 8.74, and above the 200-day MA of 8.17, indicating a bullish trend. The MACD of 0.99 indicates Negative momentum. The RSI at 68.76 is Neutral, neither overbought nor oversold. The STOCH value of 90.99 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:VICO.

Vicore Pharma Holding AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	kr6.00B	8.76	-28.73%	2.23%	51.33%	18.74%
HNSA	49 Neutral	kr2.45B	―		―	20.12%	40.54%
VICO	45 Neutral	kr2.72B	―	-40.15%	―	-94.25%	9.47%
BOVNF	―	$267.55M	―	-45.80%	―	―	―
8F8	―	€83.00M	―	-48.22%	―	―	―
6XP	―	€138.47M	―	-41.54%	―	―	―
7V3	―	€64.69M	―	-167.55%	―	―	―